Biogen Media |

All Press Releases

Biogen Announces Webcast of Virtual Annual Meeting of Stockholders
5/19/16 4:01 pm EDT
Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs
5/16/16 7:00 am EDT
Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B
5/13/16 2:47 am EDT
Biogen Announces Intent to Spin off Its Hemophilia Business
5/3/16 7:30 am EDT
Adam Koppel, Executive Vice President, Strategy and Business Development, to Return to Bain Capital
4/29/16 11:00 am EDT
Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis
4/29/16 7:39 am EDT
Biogen Appoints Michael Ehlers Executive Vice President, Research and Development
4/27/16 9:15 am EDT
Biogen Reports First Quarter 2016 Revenues of $2.7 Billion
4/21/16 7:15 am EDT
Data Presented at AAN Highlight Impact of ZINBRYTA™ (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action
4/20/16 7:30 am EDT
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
4/18/16 7:30 am EDT

Biogen Announces Webcast of Virtual Annual Meeting of Stockholders
5/19/16 4:01 pm EDT
Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs
5/16/16 7:00 am EDT
Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B
5/13/16 2:47 am EDT
Biogen Announces Intent to Spin off Its Hemophilia Business
5/3/16 7:30 am EDT
Adam Koppel, Executive Vice President, Strategy and Business Development, to Return to Bain Capital
4/29/16 11:00 am EDT
Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis
4/29/16 7:39 am EDT
Biogen Appoints Michael Ehlers Executive Vice President, Research and Development
4/27/16 9:15 am EDT
Biogen Reports First Quarter 2016 Revenues of $2.7 Billion
4/21/16 7:15 am EDT
Data Presented at AAN Highlight Impact of ZINBRYTA™ (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action
4/20/16 7:30 am EDT
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
4/18/16 7:30 am EDT